Toggle Dropdown
Groups
Announcements
Projects
Ideas
Welcome guest
Log in
Practice
My Requests
All Requests
Drill Partners
Digital games
Projects
Goals
Loading
Loading...
0
0
Early Anti-VEGF Isn't Worth Cost in Diabetic Retinopathy - Medscape
4/25/23 at 5:23pm
Organization
Medscape
Author
Donavyn Coffey
25 words
0
Comments
A drug tested on patients with nonproliferative diabetic retinopathy did not improve vision outcomes.
Health Conditions
Health
Vision Care
Worth Cost
Diabetic Retinopathy
Medscape
vision outcomes
You are the first to view
https://www.medscape.com/viewarticle/991112
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...